Will Canopy Growth Stock Continue to Surge in September 2023?

Canopy Growth stock has surged over 70% in the past week. Is WEED stock a good buy right now?

| More on:
A person holds a small glass jar of marijuana.

Source: Getty Images

Shares of cannabis producers, including Canopy Growth (TSX:WEED) have been on an absolute tear in recent trading sessions. Since Aug. 30, Canopy Growth stock has surged over 70%, valuing the company at a market cap of $740 million.

Despite these outsized gains, WEED stock continues to trade 98.6% below all-time highs, trailing the broader markets by a wide margin in the past five years.

Let’s see what has driven the recent uptick in this marijuana stock, and if it can sustain the momentum in September 2023.

Is the U.S. legalizing cannabis use?

Last week, a Bloomberg report stated a top official from the U.S. Department of Health and Human Services (HHS) sent a letter to the Drug Enforcement Agency (DEA) to remove marijuana from the list of Schedule I drugs.

Currently, marijuana is classified as a Schedule I drug, which is typically defined as a drug with no medical use and a high potential for abuse. Other drugs, including heroin and LSD, are also classified under Schedule I.

Expectedly, the DEA stated it would commence a review before it makes a decision to declassify marijuana. Does this mean the U.S. government is on the cusp of legalizing or at least decriminalizing the recreational use of marijuana at the federal level?

I believe it might still take a few more years for the U.S. to make a landmark judgment on this issue. However, during the presidential campaign back in 2020, the Democrats claimed they would decriminalize marijuana use at the federal level.

What’s next for Canopy Growth stock?

The legalization of pot south of the border will act as a massive tailwind for Canopy Growth and other Canadian licensed producers, as the U.S. is the largest marijuana market in the world.

Currently, Canadian marijuana producers are wrestling with several structural issues ranging from overvalued acquisitions to cannibalization from the illegal markets and oversupply of cannabis, leading to lower profit margins and high inventory levels.

In the first quarter (Q1) of 2024 (ended in June), Canopy Growth reported revenue of $108.7 million, an increase of 3% year over year. Its high-margin medical marijuana sales stood at $14.4 million, compared to $13.4 million in the year-ago period.

In the last two years, Canopy Growth has focused on lowering its cost base by closing down manufacturing facilities. It reduced costs by $172 million in Q1 but still reported an EBITDA (earnings before interest, tax, depreciation, and amortization) loss of $57 million, compared to $78 million in the year-ago period.

Canopy Growth is among the largest marijuana producers in Canada and enjoys a first-mover advantage. But Bay Street forecasts the company to increase sales by just 5% year over year to $423.6 million in fiscal 2024.

Moreover, sales from Canopy’s core business declined significantly in the June quarter, which was offset by strong performance for products such as sports hydration, vaporizers, and wellness.

Canopy Growth ended Q1 with $571 million in cash and $1 billion in debt. It aims to reduce debt to $437 million by the end of fiscal 2024. But with a cash outflow of $151 million in Q1, Canopy Growth will have to raise additional capital and support its cash burn rates, diluting shareholder wealth in the process.

Canopy Growth stock remains a high-risk investment due to its weak fundamentals, tepid top-line growth estimates, and uninspiring profit margins.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »